1
|
Zhong Y, Lin Z, Lin X, Lu J, Wang N, Huang S, Wang Y, Zhu Y, Shen Y, Jiang J, Lin S. IGFBP7 contributes to epithelial-mesenchymal transition of HPAEpiC cells in response to radiation. J Cell Biochem 2019; 120:12500-12507. [PMID: 30834595 DOI: 10.1002/jcb.28516] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2018] [Revised: 12/05/2018] [Accepted: 12/06/2018] [Indexed: 12/13/2022]
Abstract
Radiation-induced lung injury (RILI) frequently occurs in patients with thoracic malignancies. In response to radiation, alveolar epithelial cells (AEC) undergo epithelial-mesenchymal transition (EMT) and contribute to the pathogenesis of RILI. Insulin-like growth factor binding protein 7 (IGFBP7) is reported as a downstream mediator of transforming growth factor-β1 (TGF-β1) pathway, which plays a crucial role in radiation-induced EMT. In the present study, the levels of IGFBP7 and TGF-β1 were simultaneously increased in experimental RILI models and radiation-treated AEC (human pulmonary alveolar epithelial cells [HPAEpic]). The expression of IGFBP7 in radiation-treated HPAEpic cells was obviously inhibited by the specific inhibitor of TGF-β receptor antagonist SB431542 and TGF-β1 neutralizing antibody, and time-dependently enhanced by TGF-β1 treatment. Moreover, IGFBP7 knockdown significantly attenuated the effects of radiation on morphology change, cell migration, expression of EMT-related markers (E-cadherin, α-SMA, and Vimentin), and phosphorylation of extracellular-signal-regulated kinase (ERK). The effects of IGFBP7 overexpression on the expression of EMT-related markers were partially reversed by the ERK inhibitor PD98059. In conclusion, IGFBP7, was enhanced by TGF-β1, may be involved in radiation-induced EMT of AEC via the ERK signaling pathway, thus contributing to the pathogenesis of RILI.
Collapse
Affiliation(s)
- Yazhen Zhong
- Oncology Department, Hangzhou Hospital of Traditional Chinese Medicine, GuangXing Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
| | - Zechen Lin
- Department of Oncolgy, Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
| | - Xianlei Lin
- Oncology Department, Hangzhou Hospital of Traditional Chinese Medicine, GuangXing Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
| | - Jinhua Lu
- Department of Oncolgy Comprehensive Treatment, Hangzhou Cancer Hospital, Hangzhou, China
| | - Nan Wang
- Department of Oncolgy, The First People's Hospital of Xiaoshan Hangzhou, Hangzhou, China
| | - Siyu Huang
- Department of Oncolgy, Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
| | - Yuanyuan Wang
- Department of Oncolgy, Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
| | - Yuan Zhu
- Department of Oncolgy, Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
| | - Yiwei Shen
- Department of Oncolgy, The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
| | - Jing Jiang
- Department of Oncolgy, The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
| | - Shengyou Lin
- Oncology Department, Hangzhou Hospital of Traditional Chinese Medicine, GuangXing Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
| |
Collapse
|